Search
benznidazole
Indications:
- Chagas disease (Trypanosoma cruzi)
- FDA-approved Aug 2017 for use in children 2-12 years of age [3]
Dosage:
- 5-8 mg/kg/day PO every 12 hours for 60 days
Adverse effects:
1) polyneuropathy
2) rash
3) granulocytopenia
4) angioedema [4]
5) symptoms, generally resolve when dosage is reduced or therapy is discontinued
Mechanism of action:
- nitroimidazole antimicrobial
- generates radical species in both aerobic & anaerobic conditions capable of damaging parasitic DNA
- inhibits DNA, RNA, and protein synthesis within the Trypanosoma cruzi parasite.
Interactions
drug interactions
Related
Chagas disease
General
antiprotozoal agent
nitroimidazole
Database Correlations
PUBCHEM cid=31593
References
- Harrison's Principles of Internal Medicine, 14th ed.
Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 1194
- Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M,
Alvarez MG, Postan M, Armenti A.
Long-term cardiac outcomes of treating chronic Chagas disease
with benznidazole versus no treatment: a nonrandomized trial.
Ann Intern Med. 2006 May 16;144(10):724-34.
PMID: 16702588
- Pinto Dias JC.
The treatment of Chagas disease (South American trypanosomiasis).
Ann Intern Med. 2006 May 16;144(10):772-4. No abstract available.
PMID: 16702594
- FDA News Release. Aug 29, 2017
FDA approves first U.S. treatment for Chagas disease.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573942.htm
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Rothaus C
Under Our Very Eyes.
NEJM REsident 360. March 4, 2020
https://resident360.nejm.org/clinical-pearls/under-our-very-eyes
- Benznidazole prescribing information.
Exeltis USA, Inc. Florham Park, NJ. August, 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209570lbl.pdf